Fluorouracil News and Research

RSS

Fluorouracil is a drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite. Also called 5-fluorouracil and 5-FU.

Spectrum's FUSILEV sNDA accepted by FDA for review

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the complete response regarding its supplemental New Drug Application (sNDA) for FUSILEV® (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.

29 Nov 2010

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.

19 Nov 2010

Study demonstrates potent anticancer properties of quinoxalinyl-piperazine compounds

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry [18:7966-7974, 2010] on the anticancer activity of quinoxalinyl-piperazine compounds.

9 Nov 2010

Spectrum submits complete response to FDA's CRL for FUSILEV to treat colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Friday, October 29, 2010 it submitted a complete response to the "Complete Response" letter issued by the U.S. Food and Drug Administration (FDA), regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.

1 Nov 2010

Novel small molecule inhibitors may provide new therapy for colon cancer

Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

Genentech, a member of the Roche Group today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic (cancer that has spread) cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for their metastatic disease.

21 Oct 2010

Amgen to present oncology portfolio results at ESMO Congress

Amgen today announced that results from several important studies from the Company's ncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.

6 Oct 2010

Amgen announces PRIME '203' and '181' Phase 3 trial results

Amgen today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC), respectively, were published online in the Journal of Clinical Oncology.

5 Oct 2010

Researchers discover treatment improves overall survival in pregnant women with breast cancer

Long associated with a worse outcome, researchers at The University of Texas MD Anderson Cancer Center have discovered that women treated for breast cancer while pregnant, in fact, have improved disease free survival and a trend for improved overall survival compared to non-pregnant women treated for the disease.

30 Sep 2010

Study: Capecitabine with concurrent radiation is effective for treating gastric cancer

Gastric cancer is a major cause of cancer deaths in the world. The outcome of large gastric tumors and those with lymph node involvement remains poor after surgical resection. The optimal adjuvant therapy after surgical resection remains to be determined.

21 Sep 2010

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VELOUR clinical trial of aflibercept (VEGF Trap) in patients with metastatic colorectal cancer (mCRC) will continue to completion as planned, with no modifications due to efficacy or safety concerns. This decision is based on the recommendation of an Independent Data Monitoring Committee (IDMC) following a planned interim analysis.

9 Sep 2010

Gemcitabine does not improve survival compared with fluorouracil plus folinic acid in resected pancreatic cancer

Use of gemcitabine, a drug that can be effective in treating advanced and resected pancreatic cancer, did not result in improved overall survival after pancreatic cancer resection (surgical removal) compared to patients who received fluorouracil and folinic acid, another treatment regimen that has shown effectiveness, according to a study in the September 8 issue of JAMA.

8 Sep 2010

ESPAC-3 trial shows promising results to prevent pancreatic cancer

A major international trial has shown a commonly used chemotherapy drug is as effective at helping prevent pancreatic cancer returning after surgery as the more expensive standard chemotherapy treatment, reveals a study published in the Journal of the American Medical Association today (Wednesday).

8 Sep 2010

Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera

Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).

27 Aug 2010

Trial shows positive results for radioembolisation technique for colorectal cancer liver metastases treatment

Using the innovative technique of radioembolisation to treat patients with inoperable colorectal cancer liver metastases who have failed all standard-of-care chemotherapy options can more than double the time until their disease progresses, according to the final results of a Phase III randomised controlled trial published in the prestigious Journal of Clinical Oncology.

20 Aug 2010

Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer

Amgen today announced top-line results from a randomized Phase 3 trial evaluating Vectibix as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer. The data showed the addition of Vectibix to platinum-based chemotherapy did not result in a statistically significant improvement in overall survival, the primary endpoint, compared to chemotherapy alone.

12 Aug 2010

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.

9 Aug 2010

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.

28 Jul 2010

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Keryx Biopharmaceuticals, Inc. today announced that abstract O-0017, entitled "Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line Metastatic CRC" has been selected for oral presentation at the upcoming 12th World Congress on Gastrointestinal Cancer, to be held in Barcelona, Spain from June 30 - July 2, 2010.

30 Jun 2010

Nektar commences dosing in Phase 1 study of NKTR-102 in combination with 5-FU/leucovorin

Nektar Therapeutics announced today that the first patients have been dosed in a new Phase 1 dose-escalation clinical study to evaluate NKTR-102, the company's lead oncology compound, in combination with 5-fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers. The study is being conducted at University Hospitals Case Medical Center of the Case Comprehensive Cancer Center in Cleveland, Ohio.

24 Jun 2010